Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-10-09EMA Authorised: Adasuve (loxapine) — Ferrer Internacional S.A.
The EMA authorised Adasuve (loxapine) by Ferrer Internacional S.A. for use in schizophrenia and bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: Brain Circuitry Analysis in Bipolar Disorder
This update notes the termination of a clinical trial investigating brain circuitry analysis in individuals with bipolar disorder.
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness [NA]
A clinical trial record describing a study on the acceptability and feasibility of a work-oriented social-cognitive skills training for vete…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Disorder [NA]
This update describes a study validating a composite medical device that uses a blood biomarker-based algorithm and the MDQ to diagnose Bipo…
-
FDA approval · 2025-10-07FDA Approved: LAMOTRIGINE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lamotrigine as an original application, authorizing the first generic version of lamotri…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness
This update describes an initiative to create a global research database that links genetic information with long-term health data to improv…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study [Phase 2]
A Phase 2 proof-of-concept trial of bezafibrate for bipolar depression is currently recruiting, sponsored by Massachusetts General Hospital.
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Enhanced Brief CBT for Suicidal Inpatients With Mood Disorders [NA]
A clinical trial update describing an enhanced brief cognitive behavioral therapy program for suicidal inpatients with mood disorders; the s…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Mental Health Mission Mood Disorder Cohort Study
Clinical trial update from the University of Oxford for a mood disorder cohort study. The trial is currently not recruiting and covers major…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes [Phase 3]
Phase 3 clinical trial update evaluating methods to estimate and reduce cardiovascular risk in patients with schizophrenia using lipid measu…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Norwegian Mental Illness Heart Health Study [NA]
This clinical trial update indicates the Norwegian Mental Illness Heart Health Study is currently recruiting, studying cardiovascular and me…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Behavioural Activation Therapy and Esketamine for Resistant Depression [NA]
A clinical trial evaluating behavioural activation therapy in combination with esketamine for treatment-resistant depression and related moo…
-
FDA approval · 2025-09-30FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: The Efficacy of a Transdiagnostic Sleep and Circadian Intervention for Patients With Mental Disorders and Sleep Problems [NA]
Completed clinical trial evaluating the efficacy of a transdiagnostic sleep and circadian intervention for adults with depression, bipolar d…
-
FDA approval · 2025-09-29FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Lamotrigine from Zydus Pharmaceuticals USA Inc., resulting in clearance for a generic lamotrigin…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Neuronavigation rTMS to Improve Depressive Episodes of Bipolar Disorder in Adolescent [NA]
This clinical trial update indicates that a neuronavigation-guided repetitive transcranial magnetic stimulation (rTMS) study for depressive …
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Group-based Psychoeducation for Relatives of Patients With Bipolar Disorder, a Randomized Controlled Trial [NA]
A randomized controlled trial evaluating group-based psychoeducation for relatives of patients with bipolar disorder has completed.
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. [Phase 3]
A Phase 3 clinical trial evaluating six weeks of intensified pharmacological treatment versus treatment as usual for bipolar depression is c…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Effects of Altitude-like Cognition Training on Neuroplasticity and Cognitive Functions [NA]
A completed clinical trial evaluating altitude-like cognition training for improving neuroplasticity and cognitive function in people with c…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: Feasibility and Preliminary Results of the Efficacy of Blue-Blocking Glasses on Manic Symptoms in Bipolar Disorder [NA]
Feasibility and preliminary results of blue-blocking glasses for reducing manic symptoms in Bipolar I Disorder; the trial is currently recru…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Assessment and Treatment for Chronic Pain in Veterans With Serious Mental Illness [NA]
This clinical trial update notes the completion of a study evaluating assessment and treatment approaches for chronic pain in veterans with …
-
EMA withdrawal · 2025-09-23EMA Withdrawn: Olanzapine Apotex (olanzapine) — Apotex Europe BV
The EMA has withdrawn Olanzapine Apotex, an olanzapine product from Apotex Europe BV.
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions [Phase 1]
Phase 1 pharmacokinetic study evaluating VHX-896 in combination with iloperidone tablets under steady-state conditions; the study has comple…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) [Phase 3]
Phase 3 trial evaluating dexmedetomidine for agitation associated with schizophrenia and bipolar disorder has completed.
-
FDA approval · 2025-09-17FDA Approved: ZIPRASIDONE — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for ziprasidone from Dr. Reddy's Laboratories Limited, indicating regulatory action on an existi…